DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus

Information source: Novartis
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Aliskiren (Drug); Valsartan (Drug); Placebo for Aliskiren (Drug); Placebo for Valsartan (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Novartis

Official(s) and/or principal investigator(s):
Novartis, Study Director, Affiliation: Novartis

Summary

The purpose of the study was to evaluate the blood pressure (BP)-lowering efficacy of the combination of aliskiren and valsartan, as initial therapy, compared to valsartan monotherapy in Type II Diabetic patients with Stage II hypertension.

Clinical Details

Official title: An 8 Week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Antihypertensive Efficacy and Safety of Aliskiren Administered in Combination With Valsartan Versus Valsartan Alone in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (MASBP) at Week 8

Secondary outcome:

Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP)

Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure (MADBP) at Week 8

Change From Baseline in Mean 24-hour Ambulatory Pulse Pressure (MAPP) at Week 8

Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)

Change From Baseline in Mean Sitting Pulse Pressure (MSPP) at Week 8

Percentage of Patients Achieving Blood Pressure Control

Percentage of Responders

Change From Baseline in Plasma Renin Activity (PRA) at Week 8

Change From Baseline in Plasma Renin Concentration (PRC) at Week 8

Change From Baseline in Plasma Aldosterone at Week 8

Number of Patients With Adverse Events, Serious Adverse Events and Death

Detailed description: When protocol Amendment 2 was released, there were patients who had already been randomized into the study. These patients were included in the trial prior to making changes to the eligibility criteria. Thus, the study contains 2 distinct cohorts. Cohort 1 contains those patients who had already been randomized, and had been deemed eligible based on the original inclusion/exclusion criteria, prior to Amendment 2. No new patients were randomized to Cohort 1. Cohort 2 contains patients who were randomized, having been found eligible based on the revised inclusion/exclusion criteria, after Amendment 2. Differences in the inclusion and exclusion criteria are indicated below.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients who are eligible and able to participate in the study, and who give written

informed consent before any assessment is performed.

- Men or women 18 years and older.

- Patients with Type 2 diabetes mellitus with an HbA1c ≤ 9 % at visit 1 and on a stable

anti-diabetic regimen not including insulin or stable diet and exercise for at least 4 weeks prior to visit 1. Cohort 1:

- Patients with Stage 2 systolic hypertension, defined as having a MSSBP ≥160 mmHg and

<200 mmHg at Visit 5 (randomization).

- Patients who have been newly diagnosed with hypertension or who have not received

antihypertensive medication for at least 4 weeks (28 days) prior to Visit 1 must have MSSBP ≥ 160 mmHg and < 200 mmHg at Visit 1, otherwise, they will be considered screen failures.

- Patients receiving antihypertensive medication must have a MSSBP of ≥150 mmHg and

<200 mmHg at Study Visit 1, otherwise they will be considered screen failures. Cohort 2:

- Patients must also have had a mean 8-hour daytime ambulatory systolic blood pressure

(ASBP) ≥140 mmHg AND mean 8-hour daytime ambulatory diastolic blood pressure (ADBP) ≥90 mmHg at Visit 5 (randomization).

- Hypertensive patients with MSSBP ≥150 mmHg and but <200 mmHg AND MSDBP ≥95 but <120

mmHg at Visit 5 (randomization).

- Patients who had been newly diagnosed with hypertension or who had not received

antihypertensive medication for at least 4 weeks (28 days) prior to Visit 1 must have had MSSBP ≥150 mmHg but <200 mmHg and MSDBP ≥95 but <120 mmHg at Visit 1, otherwise, they were considered screen failures. Exclusion Criteria:

- Office blood pressure measured by cuff (MSSBP ≥200 mmHg or MSDBP ≥120 mmHg).

- History or evidence of secondary hypertension of any etiology.

- Refractory hypertension, defined as having uncontrolled BP (≥140/90 mmHg) while

receiving 3 antihypertensive medications at the maximum approved dose of each drug, one of which must be a diuretic.

- Patients treated with more than 3 antihypertensive medications (each component of a

combination drug counts individually).

- Type 2 diabetes mellitus currently requiring insulin treatment.

- modification of diet in renal disease (MDRD) estimated glomerular filtration rate

(eGFR) < 60 mL/min/1. 73m2

- Serum sodium less than lower limit of normal, serum potassium < 3. 5 mEq/L or ≥ 5. 3

mEq/L at Visit 1.

- Known Keith-Wagener grade III or IV hypertensive retinopathy.

Cohort 1:

- Patients with known diabetic retinopathy (eg, having a history of laser therapy for

diabetic retinopathy) or diabetic neuropathy (eg, receiving medication for diabetic neuropathy). Cohort 2:

- Patients with known diabetic retinopathy or diabetic neuropathy and/or having a history

of treatment for either. Other protocol-defined inclusion/exclusion criteria applied.

Locations and Contacts

Investigative Site, Newark, Delaware USA, United States

Investigative Site, Kansas, Missouri, United States

Investigative Site, Camden, New Jersey, United States

Investigative Site, Philadelphia, Pennsylvania, United States

Additional Information

Starting date: May 2009
Last updated: December 3, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015